A Phase II Clinical Study of the Treatment of Disitamab Vedotin RC48) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Expressing HER2
Latest Information Update: 23 Apr 2024
At a glance
- Drugs Disitamab vedotin (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
Most Recent Events
- 16 Apr 2024 Planned End Date changed from 1 May 2026 to 17 Apr 2026.
- 16 Apr 2024 Planned primary completion date changed from 1 Mar 2025 to 17 Apr 2025.
- 16 Apr 2024 Planned initiation date changed from 1 Mar 2024 to 17 Apr 2024.